This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in company filings.
Does Bright Minds Biosciences (DRUG) pay a dividend?
Bright Minds Biosciences (DRUG) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Bright Minds Biosciences (DRUG) pay a dividend?+
No. Bright Minds Biosciences (DRUG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Bright Minds Biosciences return cash to shareholders?+
It largely does not. Bright Minds Biosciences pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Bright Minds Biosciences afford to pay a dividend?+
Not currently. Bright Minds Biosciences's free cash flow is negative at -C$25 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Bright Minds Biosciences.
Peers
Biotechnology · Pick stocks to compare with DRUG
Held by ETFs
DRUG is in 10 US ETFs. The largest of them, with DRUG's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
Fidelity Enhanced Small Cap ETFFESM0.01%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.02%of the fund
iShares Micro-Cap ETFIWC0.10%of the fund
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC0.05%of the fund
SPDR S&P International Small Cap ETFGWX0.06%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DRUG
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.